3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow James Murrough: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| XEN1101 for Major Depressive Disorder XEN1101, Placebo - Major Depressive Disorder | Phase 2 | Completed | James Murrough | 60 | 2021-10-19 | 2026-11-06 |
| Study to Treat Major Depressive Disorder With a New Medication Ezogabine, Placebos - Depressive Disorder, Anhedonia | Phase 2 | Completed | James Murrough | 45 | 2017-09-25 | 2020-10-23 |
| Nuedexta in Treatment-Resistant Major Depression dextromethorphan/quinidine - Major Depressive Disorder, Treatment Resistant | Phase 2 | Completed | James Murrough | 20 | 2013-07-01 | 2018-06-11 |
Depression (3) · Anhedonia (2) · Depressive Disorder, Major (2) · Depressive Disorder (1)
XEN1101 (1) · dextromethorphan - quinidine combination (1) · ezogabine (1)
United States (3)
PMID 28478356, PMID 33653118, PMID 41001561
R33MH111932 (1), R61MH111932 (1)